Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy
- 224 Downloads
Purpose Neoadjuvant chemotherapy may modify the yield of involved axillary lymph nodes. The purpose of this study was to identify the clinical significance of the involved nodal ratios in patients with stage II/III breast cancer treated with neoadjuvant chemotherapy. Methods Two hundred and five stage II and III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this prospective study. The patients received three cycles of neoadjuvant chemotherapy followed by curative surgery, either breast-conserving surgery or mastectomy with axillary lymph node dissection, and received three additional cycles of docetaxel/doxorubicin chemotherapy as adjuvant. Adjuvant radiotherapy and hormonal therapy were given after adjuvant chemotherapy when indicated. Results The median follow-up duration was 28.9 months. The overall response rate (RR) for neoadjuvant chemotherapy was 77.6%. The mean nodal ratio was 0.29 (range, 0–1.0; nodal ratio ≤0.25, 121 [59.0%] vs. >0.25, 84 [41.0%]). Relapse free survival (RFS) of the patients who had a nodal ratio >0.25 was significantly shorter (Hazard Ratio (HR) = 2.701, P = 0.001). A nodal ratio >0.25 was also associated with a shorter overall survival (OS) (HR = 4.109, P = 0.006). However, RFS and OS were not different according to the absolute number of involved nodes (ANIN) (P = 0.166, P = 0.248, respectively). In multivariate analysis, the nodal ratio was an independent prognostic factor for RFS and OS (HR = 4.246, P < 0.001; HR = 7.764, P < 0.001). Conclusion Axillary nodal ratios have an independent prognostic value in stage II/III breast cancer treated with neoadjuvant chemotherapy. Nodal ratio might be a useful tool to identify the patients at high risk of relapse in the neoadjuvant setting.
KeywordsNodal ratio Neoadjuvant chemotherapy Prognosis Breast cancer Nodal stage
This study was supported by a Korean Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2006-531-E00034), a grant from the Seoul National University Hospital Research Fund (05-800-20050148). We would like to thank our clinical research nurse Kyung-Hee Lee for her assistance of clinical trial. We also thank Dr. Cunningham, English editor of BioMed Proofreading for his assistance. This study was presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30th–June 3rd, 2008.
- 10.Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar
- 19.Keam B, Im SA, Kim HJ et al (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7(1):203–213. doi: 10.1186/1471-2407-7-203 PubMedCrossRefGoogle Scholar
- 20.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216. doi: 10.1093/jnci/92.3.205 PubMedCrossRefGoogle Scholar
- 24.Vinh-Hung V, Vlastos G, Fioretta G et al (2007) Nodal ratios as an alternative to pN-staging in node-positive breast cancer: a validation study. Breast Cancer Res Treat 106(Suppl 1):S215 (abst 5027)Google Scholar
- 25.Martinez-Trufero J, Artal-Cortes A, Zorrilla M et al (2001) New distinctive features on the study of prognostic factors in patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NAC). Proc Am Soc Clin Oncol 20 (abst 3069)Google Scholar
- 33.Pierga JY, Mouret E, Diéras V, Laurence V, Beuzeboc P, Dorval T, Palangié T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P et al (2000) Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83(11):1480–1487. doi: 10.1054/bjoc.2000.1461 PubMedCrossRefGoogle Scholar